Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652674 | 1.00 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3DPP4DPP7 | |
| SCHEMBL7957756 | 1.00 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3DPP4DPP7 | |
| SCHEMBL2295017 | 0.89 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3NMT1PPARG | |
| SCHEMBL2295009 | 0.89 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3NMT1PPARG | |
| Hydrochloric Acid SCHEMBL6478645 | 0.87 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3PPARGPPARA | |
| Hydrochloric Acid SCHEMBL6478641 | 0.87 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3PPARGPPARA | |
| Trifluoroacetic Acid SCHEMBL4544157 | 0.86 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3DPP4DPP7 | |
| SCHEMBL9921946 | 0.82 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3DPP4DPP7 | |
| SCHEMBL3441646 | 0.82 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3DPP4DPP7 | |
| SCHEMBL18607979 | 0.81 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| EP-4732286-A2 | COMPOSITIONS AND METHODS FOR ENCRYPTING, STORING, AND DECRYPTING INFORMATION IN OLIGOMERS | Board of Regents, The University of Texas System (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4269400-B1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE SA (PL) | 2025-07-09 | — | — | EP | disclosed |
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | MOLECURE S.A. (PL) | 2025-06-10 | — | — | US | disclosed |
| WO-2025058677-A2 | COMPOSITIONS AND METHODS FOR ENCRYPTING, STORING, AND DECRYPTING INFORMATION IN OLIGOMERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| EP-4269400-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Molecure SA (PL) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269400-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Molecure SA (PL) | 2023-11-01 | — | — | EP | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-1092435-A1 | REMEDIES FOR DIABETES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001009127-A1 | BENZOXAZINE DERIVATIVES AND THEIR THERAPEUTIC USE | AVENTIS PHARMA S.A. (FR) | 2001-02-08 | — | — | WO | disclosed |
| US-5942387-A | Combinatorial process for preparing substituted thiophene libraries | ELI LILLY AND COMPANY (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0825164-A2 | Scavenger assisted combinatorial process for preparing libraries of amides, carbamates and sulfonamides | ELI LILLY AND COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| EP-0818431-A1 | Scavenger assisted combinatorial process for preparing libaries of secondary amine compounds | ELI LILLY AND COMPANY (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0816309-A1 | Scavenger assisted combinatorial process for preparing libraries of urea and thiourea compounds | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5466687-A | Anticholesterol agents | DR. KARL THOMAE GMBH (DE) | 1995-11-14 | — | — | US | disclosed |
| EP-0596326-B1 | Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production | THOMAE GMBH DR K (DE) | 1995-08-23 | — | — | EP | disclosed |
| EP-0596326-A1 | Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production | Dr. Karl Thomae GmbH (DE) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | SLC6A4 4724/4885SLC6A2 4847/4885SLC6A3 4837/4885 |
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | CHI3L1, CHI3L2, CHIA | SLC6A4 4021/4885SLC6A2 4753/4885SLC6A3 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.